Expression and regulation of HIF-1alpha in macrophages under inflammatory conditions; significant reduction of VEGF by CaMKII inhibitor

Johanna Westra*, Elisabeth Brouwer, Ingrid AM van Roosmalen, Berber Doornbos-van der Meer, Miek A van Leeuwen, Marcel D Posthumus, Cees GM Kallenberg

Abstract

Background: Macrophages expressing the pro-angiogenic transcription factor hypoxia-inducible factor (HIF)-1alpha have been demonstrated in rheumatoid arthritis (RA) in the synovial tissue. Aim of the present study was to investigate intracellular signal transduction regulation of pro-inflammatory HIF-1 alpha expression in macrophages to identify possible new intervention strategies. We investigated the effects of CaMKII-inhibitors amongst other kinase inhibitors, on HIF-1 alpha expression and downstream production of pro-angiogenic factors in macrophages.

Methods: Differentiated THP-1 cells and synovial fluid (SF) macrophages were stimulated with 1 μg/ml LPS with or without pretreatment with specific inhibitors of the ERK pathway (PD98059), the PI3K pathway (LY294002), and the CaMKII pathway (KN93 and SMP-114). mRNA and protein expression of HIF-1 alpha, VEGF, MMP-9, and IL-8 was measured in cell lysates and cell supernatants.

Results: HIF-1 alpha protein expression in LPS-stimulated THP-1 macrophages could be blocked by ERK- and PI3K-inhibitors, but also by the CaMKII inhibitor KN93. THP-1 and SF macrophages produced high levels of VEGF, IL-8, and MMP-9, and VEGF protein production was significantly inhibited by PI3K-inhibitor, and by both CaMKII inhibitors. LPS stimulation in an hypoxic environment did not change VEGF levels, suggesting that LPS induced VEGF production in macrophages is more important than the hypoxic induction.

Conclusions: Expression of HIF-1 alpha and downstream effects in macrophages are regulated by ERK-, PI3K, but also by CaMKII pathways. Inhibition of HIF-1α protein expression and significant inhibition of VEGF production in macrophages was found using CaMKII inhibitors. This is an unknown but very interesting effect of the CaMKII inhibitor SMP-114, which has been in clinical trial as DMARD for the treatment of RA. This effect may contribute to the anti-arthritic effects of SMP-114.

Background

Macrophages are known to play an important role in inflammatory diseases such as rheumatoid arthritis (RA), as the rheumatoid synovium is intensively infiltrated by macrophages and their numbers correlate well with articular destruction [1] and clinical scores [2]. It has long been recognized that synovial fluids from RA patients are hypoxic, acidic, and have low glucose and high lactate levels [3]. This is indicative of an anaerobe situation, which has been confirmed by measuring oxygen levels in the synovium. [4]. A microenvironment of hypoxia leads to the formation of an ubiquitously expressed transcription factor, hypoxia-inducible factor (HIF-1), which regulates the expression of genes that allows cells to use anaerobic metabolism to generate energy for survival and secondly, to promote angiogenesis for oxygen supply [5]. The heterodimeric transcription factor HIF is composed of two basic helix-loop-helix (bHLH) proteins (HIF-1α and HIF-1β). The HIFα/β dimer binds to a core DNA motif in the hypoxia responsive elements, which are associated with a broad range of target genes, such as vascular endothelial growth factor (VEGF), erythropoietin (EPO), and glucose-transporter-1
(GLUT-1), promoting angiogenesis, erythropoiesis, cell growth and migration, and a switch to a glycolytic cell metabolism [6]. HIF-1β, also known as ARNT (aryl hydrocarbon receptor nuclear transporter) is constitutively expressed, whereas HIF-1α is induced, amongst other stimuli, by hypoxia. During normoxia HIF-1α is hydroxylated at specific prolyl residues leading to degradation through the ubiquitin-proteasome pathway [7,8]. However, under normoxic circumstances HIF-1α can be stabilized in cell lines and primary cell-cultures by other stimuli, such as mechanical stress, hormones, cytokines, growth factors but also by reactive oxygen and nitrogen particles [9]. In ligand-induced activation of HIF-1, in general two major phosphorylation pathways are involved, the phosphatidylinositol-3-kinase (PI3K) and the mitogen-activated protein kinase (MAPK) pathway [10]. Frede et al [11] reported involvement of the ERK (p44/p42) MAPK pathway in differentiation of the human monocytic cell line THP-1 along with increased HIF-1 activity, while increased expression of HIF-1α correlated to differentiation was also reported by others [12].

In recent reviews the possible important role of HIF-1 in RA is extensively discussed [6,13]. Especially the presence of both hypoxia and inflammatory proteins in RA both leading to HIF-1α stabilization and subsequent HIF-1 activation seems to warrant an important role for HIF-1α. Recently new small molecular drugs that have inhibitory effect on HIF-1α have been tested in arthritis models. Effects of 2 ME-2 (methoxyestradiol) were investigated in a rat CIA model and in a rat AIA model [14,15]. In the CIA model a marked suppression of synovial gene expression of bFGF and VEGF was observed, with parallel reduction of synovial blood vessels, whereas in both CIA and AIA the severity of disease was reduced. Inhibitors of Hsp90 have been shown to inhibit HIF-1 activity and were investigated in vitro and in vivo in arthritis models. They showed to inhibit paw swelling and to improve body weight. Scores for inflammation, pannus formation, cartilage damage, and bone resorption returned to normal [16].

Recently, involvement of another signal transduction pathway in HIF-1 transcriptional activity was reported, namely the Ca²⁺/Calmodulin-dependent kinase II (CaMKII) pathway [17]. Many of the cellular responses to Ca²⁺are modulated by a family of protein kinases, namely Ca²⁺/calmodulin dependent protein kinases (CaMK), among which CaMKII is ubiquitously expressed. CaMKII has been reported to play an important role in osteoclast differentiation and function [18] and to be expressed in macrophages and fibroblasts in RA synovial tissue, and also in cultured synovial fibroblasts (Tagashira S et al, poster session A, no 94, ACR meeting, Washington 2006). Recently it was shown that CaMKII activation was involved in TLR-triggered, pro-inflammatory cytokine production by macrophages [19].

In this study we investigated expression of HIF-1α in macrophages with subsequent activation both in an inflammatory and hypoxic environment, and evaluated whether this activation leads to production of proangiogenic factors. Moreover we studied the effect of specific signal transduction inhibitors both on HIF-1α expression and on downstream products of HIF-1 activation in macrophages in cell-lines as well as in macrophages isolated from synovial fluid (SF). We, hereby, included the use of a novel CaMKII inhibitor, which has been shown to have excellent efficacy in collagen-induced arthritis in rats (Furuichi et al., abstract Fri0027, EULAR, Barcelona 2007) and which has been in phase IIb clinical trial in Europe.

Methods
All chemicals used were from Sigma Chemical Co., St. Louis, MO, unless otherwise indicated. RPMI 1640 medium and gentamycin were purchased from Gibco (Life Technologies Ltd, Paisley, Scotland). Fetal calf serum (FCS) was from BioWhittaker Europe (Verviers, Belgium), and culture plates from Costar (Badhoevedorp, The Netherlands). NE-PER® Nuclear and Cytoplasmic Extraction Reagents were obtained from Pierce Technology (Rockford, IL). Anti- HIF-1α for Western Blotting was from BD Transduction labs. (BD Biosciences, Breda, the Netherlands); anti-HIF-1alpha 67sup (nr 463) for immunohistochemistry was from Abcam (Cambridge, UK). The signal transduction inhibitors LY294002, PD98059, KN-93, and the HIF-1α inhibitor YC-1 were purchased from Calbiochem (via Merck Eurolab, Amsterdam, The Netherlands). SMP-114 was supplied by Dainippon Sumitomo Pharma (Osaka, Japan). All reagents for RNA isolation and reverse transcriptase reaction were purchased from Invitrogen, Life Technologies (Gaithersburg, MD). Reagents for real-time RT-PCR were obtained from Applied Biosystems (Foster City, CA).

Cell culture of macrophages
SF was obtained from 14 patients with active RA, who were visiting our outpatient clinic. Local research ethics committee gave approval for the study and all patients had given informed consent. SF was diluted 1:1 with RPMI plus 10 mg/ml gentamicin. Subsequently mononuclear cells (MC) were isolated by Lymphoprep density gradient centrifugation. SFMCs were cultured (5 × 10⁶ cells/ml) in 2 ml RPMI + 2% human pooled serum in 6-well plates (Costar, Badhoevedorp, the Netherlands) or in 1 ml in 12-well plates at 37°C in a 5% CO₂ atmosphere. The cells that adhered after two hours were used for experiments. For hypoxia experiments cells
were incubated in an hypoxia incubator, the Ruskin
Invivo2 200, with an O2 level of 1%.
THP-1 monocyctic cells (ATCC-LGC, Middlesex, UK)
were cultured in RPMI plus additives (25 mM HEPES,
200 mM glutamine, 100 mM Na-pyruvate, 10 mg/ml gentamicin,
0.05 M β-mercaptoethanol, 2.2 μg/ml amphotericin B) supplemented with 10% FCS and were
differentiated into macrophages with 100 nM PMA
(phorbol 12-myristate 13-acetate) during 3 days in
RPMI plus 10% FCS and additives. Culture or stimula-
tion periods are indicated where relevant.

HIF-1α expression in rheumatoid synovial tissue and in
THP-1 macrophages
Synovial tissue was obtained from RA patients (n = 8),
who underwent synovectomy or joint replacement sur-
gery, and who had given informed consent. Synovial tis-
ue was formalin fixed and paraffin embedded, and 4
μM slides were cut. Sections were deparaffinised with
xylene and rehydrated with ethanol and water. Endo-
genous peroxidase activity was blocked with 0.3% hydrogen
peroxide in PBS. The sections were incubated overnight
at 4°C with monoclonal antibody HIF-1α/βsup. For
detection, the sections were incubated with peroxidase
labeled anti-mouse polymer from EnVision Kit (K4006,
DAKO, Glostrup, Denmark). Sections were also stained for
macrophages (CD68, clone PGM-1, DAKO), and
vessels (CD31, clone JC70A, DAKO).

HIF-1α expression was detected by Western blotting
in THP-1 macrophages stimulated with 1 μg/ml LPS for
6 hours or left unstimulated. Nuclear extracts were pre-
pared with the NE-PER® Nuclear and Cytoplasmic
Extraction Reagents according to the manufacturers’
instructions. Samples were loaded onto a 10% SDS-
PAGE gel and resolved by running at 120 V and 15
Watt constant. Semidry blotting onto nitrocellulose
membrane was followed by immunodetection with
anti-HIF-1α (BD Pharmeden) and anti-mouse-immuno-
globulins labeled with HRPO. Enhanced chemilumines-
cence (ECL) detection was performed according to the
manufacturer’s guidelines (Lumi-Lightplus, Roche Diagnostics).

mRNA expression of HIF-1α and VEGF
THP-1 cells (1 × 10⁶/ml) were cultured in 6-well plates
and stimulated with 1 μg/ml LPS at different time
points during differentiation. After 4 hours of stimula-
tion total RNA was isolated from the cells with TRIzol
reagent according to the manufacturers’ instructions as
described earlier [20]. DNase treatment (Ambion, Hun-
tingdon, Cambridgeshire, UK) was performed and sub-
sequently cDNA was synthesized from 2.0 μg of total
RNA using M-MLV Reverse Transcriptase and oligo
(dT)₁₄₋₁₈. For measurement of mRNA for HIF-1α,
VEGF, IL-8, matrix metalloproteinase (MMP)-9 and gly-
ceraldehyde-3-phosphate dehydrogenase (GAPDH) 1 μl
of cDNA in triplicate was used for amplification by the
Taqman real-time PCR system (ABI Prism 7900HT
Sequence Detection System, Applied Biosystems, Foster
City, CA) with specific Taqman primers/probes (Applied
Biosystems). Amplification was performed using stan-
dard conditions and calculations of fold induction were
performed as described earlier. The amount of target,
normalized to an endogenous reference (GAPDH) and
relative to the unstimulated control sample, is given by:
2⁻ΔΔCT. mRNA expression in SFM was determined in the
same way.

Determination of VEGF, IL-8, and MMP-9 levels in cell
culture supernatants
Production of pro-angiogenic factors was measured in
cell culture supernatants of THP-1 cells (0.5 × 10⁶/
0.5 ml in 24 well plates) during differentiation either
unstimulated or stimulated for 48 hours with 1 μg/ml
LPS. Effects of YC-1, a specific HIF-1α inhibitor, and of
kinase inhibitors (30 minutes pre-treatment) on protein
production was also measured in macrophage cell
supernatants after 48 hours LPS stimulation.

VEGF, IL-8, and MMP-9 levels were measured in cell
supernatants by ELISA, using matched antibody pairs
for ELISA and recombinant proteins as standards (R&D
Systems). For optimal determination of MMP-9,
precoating with F(ab)2 fragments of goat-anti-mouse
IgG-Fc (Jackson, West Grove, Pennsylvania, USA) in
0.1 M carbonate buffer (pH = 9.6) for at least 48 hours
was done before coating of the capturing antibody.
In all ELISAs, after sample incubation and binding of
the biotinylated detecting antibodies, color reaction
was performed with streptavidin-poly-HRP (Sanquin,
Amsterdam, the Netherlands) and tetramethyl-benzidin
(TMB, Roth, Karlsruhe, Germany).

Statistics
One-way ANOVA with Dunnett’s post test was per-
formed using GraphPad Prism version 4.00 for Win-
dows, GraphPad Software (San Diego, California, USA).

Results
HIF-1α expression in rheumatoid synovial tissue
First we investigated expression of HIF-1α in RA syno-
vial tissue. Following the staining procedure described
by Zhong and Semenza [21] and using monoclonal anti-
body HIF-1α/βsup we detected a nuclear staining of
HIF-1α in synovial tissues from all RA patients, which
was not restricted to the lining layer but had a diffuse
pattern throughout the tissue (figure 1A and 1D, see
arrows) [22]. Staining of synovial tissue of OA patients
showed significantly less HIF-1α staining (data not
shown). The synovial tissues also showed abundant staining for macrophages (CD68) (figure 1B) and vessels (CD31) (figure 1C).

mRNA expression of HIF-1α and VEGF in THP-1 cells and synovial macrophages
To investigate both mRNA and protein expression of HIF-1α in vitro we first measured levels of HIF-1α and VEGF mRNA in differentiated THP-1 cells and in macrophages from SF (n = 4) with realtime RTPCR. In figure 2 it is shown that HIF-1α mRNA expression is increased in THP-1 cells, and that macrophages isolated from RA SF have very high HIF-1α expression (mean fold induction of 7.9). VEGF mRNA levels were also increased in SF macrophages (mean fold induction of 5.2). IL-8 mRNA levels were increased 40-50 fold in both THP-1 and SF macrophages, and MMP-9 mRNA levels were two-fold higher in SF macrophages. Incubation of SF macrophages in an hypoxia incubator did not increase HIF-1α expression further, but did raise VEGF mRNA levels slightly (figure 3).

HIF-1α protein expression is induced during differentiation under non-hypoxic conditions and can be blocked by kinase inhibitors
Next we continued with protein expression of HIF-1α during differentiation and after stimulation. THP-1 cells under non-hypoxic conditions were induced to differentiation with 100 nM PMA and HIF-1α expression was studied in LPS stimulated or unstimulated cells at several time points (figure 4A). We observed an increased HIF-1α expression during differentiation in unstimulated cells, which was even higher after LPS stimulation.

Then we investigated the effects of the specific MEK inhibitor PD98059, the PI3K inhibitor LY294002, and the CAMKII inhibitor KN93 on HIF-1α protein expression in differentiated THP-1 cells. Figure 4B shows that the MEK inhibitor PD has an inhibitory effect at 50 μM
**Figure 2** mRNA expression of HIF-1α, VEGF, IL-8, and MMP-9 in macrophages under normoxia. HIF-1α, VEGF, IL-8 and MMP-9 mRNA levels under normoxia from differentiated THP-1 cells (macrophages) and macrophages isolated from RA synovial fluid with LPS stimulation (4 hours) and without LPS stimulation. mRNA expression was expressed as fold induction (2^ΔΔCt, Ct is threshold value), which is normalized to a household gene (GAPDH) and relative to an unstimulated sample (fold induction = 1).

**Figure 3** mRNA expression of HIF-1α and VEGF in RA SF macrophages under normoxia and hypoxia. HIF-1α and VEGF mRNA levels of synovial fluid macrophages (n = 4) under normoxic or hypoxic (1% O2) conditions with and without LPS stimulation. mRNA expression was expressed as fold induction (2^ΔΔCt, Ct is threshold value), which is normalized to a household gene (GAPDH) and relative to an unstimulated sample (fold induction = 1).
on HIF-1α expression in differentiated THP-1 cells, the PI3K inhibitor LY at 10 and 50 μM, and the CaMKII inhibitor KN at 10 μM. So these various signal transduction pathways are involved in LPS-induced HIF-1α expression in macrophages.

Production of proangiogenic factors during differentiation of THP-1 cells
To see whether differentiation of THP-1 cells leads to increased production of pro-angiogenic factors, VEGF, IL-8 and MMP-9, protein levels were measured in cell supernatants of stimulated and unstimulated cells after 0, 1, 2 and 3 days of differentiation. As can be seen in figure 5A protein production of VEGF, MMP-9 and IL-8 increased during differentiation. Preincubation with the specific HIF-1α blocker YC-1 significantly inhibited VEGF-, IL-8- and MMP-9 production in THP-1 macrophages (figure 5B). From these results we can conclude that production of these angiogenic factors in macrophages is regulated by activation of HIF-1α.

Regulation of VEGF, IL-8 and MMP-9 production
To determine which intracellular pathways are involved in production of these angiogenic factors THP-1 cells were incubated with specific inhibitors of the ERK-, PI3K-, and CaMKII pathways. Since we had found effects of the CaMKII inhibitor KN-93 on HIF-1α expression we decided to include the novel CaMKII inhibitor SMP-114 (in phase 2 clinical trial for treatment of RA). Significant inhibition of VEGF production was seen with 10 μM PD, LY and KN, but also with 3 and 10 μM SMP-114 (figure 6). KN-93 at concentration 2 μM did not inhibit VEGF production in contrast to SMP-114 at 3 μM. From previous unpublished research we know that SMP-114 can also be used at higher concentrations (30 μM) than KN-93 without becoming cytotoxic. IL-8 production was significantly inhibited by CaMKII inhibitors (KN-93 at 10 μM and SMP-114 at 30 μM). MMP-9 production was slightly increased by LPS stimulation, but decreased by PI3kinase and CaMKII inhibitors (not significant).

We then performed these studies in SF macrophages. Figure 7 shows that VEGF production in SF macrophages was significantly reduced by the PI3K-inhibitor and the CaMKII inhibitor SMP-114. SMP-114 can be safely used at this concentration, whereas KN-93 can not. IL-8 production was not affected by signal transduction inhibitors (data not shown). As stimulation of SF macrophages with LPS reduced the high constitutive production of MMP-9, inhibitors were also added to unstimulated cells. MMP-9 production was inhibited by PI3K and CaMKII inhibitors, but this did not reach statistical significance (data not shown).

Since we detected an increase in VEGF mRNA expression in SF macrophages that were incubated in an
hypoxia incubator, protein production was also measured under these circumstances. Figure 8 shows that VEGF and MMP-9 production did not increase when macrophages were stimulated with LPS in an hypoxia incubator compared to a normoxic incubator. However, PI3K and CaMKII inhibitors reduced VEGF levels as was seen under normoxia. Levels of IL-8 highly increased when the cells were incubated in hypoxia, and significant reduction was achieved with PI3K- and CaMKII inhibitors.

Discussion
In this study we showed that HIF-1α is expressed in synovial tissue from rheumatoid arthritis patients, and also in macrophages isolated from RA SF. In the inflammatory, non-hypoxic regulation of HIF-1α expression both PI3kinase and CaMKII pathways are involved, which is reflected by significant reduction in VEGF levels by specific inhibitors.

Expression of HIF-1α, the inducible part of the transcription factor HIF-1, has been described for RA synovial tissue [23,24] especially in macrophages in the synovium [25]. However contradicting results have been reported demonstrating either nuclear or cytoplasmic staining, and with or without differences between RA and OA synovial tissue [23-25]. In the field of oncology, in which many publications report HIF-1α staining, the procedure as described by Semenza’s group is considered the standard staining [21]. They described in different tissues a nuclear staining of HIF-1α, mostly with a diffuse pattern or located near necrotic areas or neovascular areas. We followed these staining procedures and found nuclear staining in 8 synovial specimens, both in the lining and in the sublining layer. Although we did not perform double staining it is likely that HIF-1α was expressed mainly by macrophages since these cells are found everywhere in the tissue. In contrast to one study [23] but in accordance with others [25], we found minor HIF-1α expression in OA synovial tissue [22]. This is in line with the nature of the tissue being inflammatory and angiogenic in RA, and less inflammatory in osteoarthritis synovial tissue.

Stabilization of HIF-1α can take place under hypoxic conditions but can also be induced by differentiation of monocytes to macrophages and by stimulation with LPS [11,12]. Macrophages isolated from RA SF come from an hypoxic environment [3], which was reflected by their high HIF-1α and VEGF mRNA levels compared to macrophages derived from THP-1 cells. Incubating these cells in an hypoxia incubator did not increase HIF-1α expression further since these cells already were hypoxic. By Western blotting we demonstrated that
HIF-1α protein expression can be inhibited by the PI3 kinase inhibitor and the CaMKII inhibitor KN93 at 10 μM in THP-1 macrophages, so there is a role for CaMKII signalling in HIF-1 regulation.

Induction of HIF-1α expression leads to production of angiogenic proteins. Both VEGF and MMP-9 levels increased during differentiation without stimulation with LPS, and this was further increased following stimulation. IL-8 production was also induced but highly increased after stimulation with LPS. When we used YC-1, (3-(5'-hydroxymethyl-2'-furyl)-1-benzyl indazole), which is considered a specific HIF-1α inhibitor) [26,27], levels of VEGF and MMP-9 were completely reduced whereas IL-8 levels were less diminished. This implies that VEGF and MMP-9 production are under control of HIF-1, whereas this is partly the case for IL-8. It has
been reported that YC-1 can induce apoptosis in vitro in cell-lines, but this is primarily at concentration higher than 5 μM, so the reduction that was seen at 1 μM is due to blocking of HIF-1 activity [28]. Incubating THP-1 macrophages with different concentrations of the signal transduction inhibitors gave a significant reduction of VEGF protein levels at 10 μM or lower concentrations for all inhibitors, but for SF macrophages this was only the case for the PI3kinase inhibitor and for SMP-114. There is often a difference between cell lines and primary cell cultures, but the data convincingly show that these pathways are crucial in HIF-1 induced VEGF production. Incubation of SF macrophages in an hypoxia incubator did not increase VEGF or MMP-9 protein production, while IL-8 production was increased. Apparently hypoxia and LPS work synergistically in induction of IL-8, which still can be inhibited by PI3K- and CaMKII inhibitors. MMP-9 levels were decreased in SFM after stimulation with LPS. Lee et al. [29] showed that in serum of conditioned media inhibitory factors are present that inhibit MMP-9 production by macrophages. Since we cultured SFM in RPMI supplemented with 2% human pooled serum, it could well be that this is the reason for suppression of MMP-9 production.

Recently it was reported that in the mouse macrophage cell line RAW264.7 LPS induced activation was enhanced by hypoxia, resulting in increased TNF-α secretion [30]. Also, Fang et al. showed that HIF-1 and HIF-2 are important transcriptional effectors in primary macrophages experiencing hypoxia, more important than NF-κB [31]. In another recent publication it was shown that LPS induces intracellular calcium release in macrophages and that CaMKII is activated after LPS-induced TLR-activation [19]. It was demonstrated that CaMKII activation directly induces cytokine production in macrophages. From these studies is clear that both hypoxia and inflammation are important in macrophage activation and that different signal transduction pathways are involved.

In this study we confirm the involvement of the PI3kinase pathway in HIF-1α regulation in THP-1 macrophages and macrophages from RA SF. We suspected a role for CaMKII inhibition initially based on a report by Yuan et al., in which they mentioned that HIF-1 transcriptional activity was dependent on CaMKII activation [17]. In our study we found that CaMKII inhibition reduces HIF-1α expression and VEGF production in stimulated macrophages. In inflammatory conditions such as RA the relevance of HIF-1 primarily lies in controlling angiogenesis, since this is an important feature of
RA. Inhibition of angiogenesis has already been investigated in a number of animal arthritis studies, via drug intervention [15], or by gene therapy [32] in rat models of arthritis. In the introduction we already mentioned animal studies with specific HIF-1 inhibitors. In humans anti-angiogenic effects are known for some drugs, for instance anti-TNF therapy induced reduction of VEGF levels in RA patients [33]. Anti-angiogenic effects are in our study now established for the CaMKII inhibitor SMP-114 in macrophages. However, this is clearly an off-target effect and although beneficial in this case effects like these need further investigation in new developed drugs.

Conclusions
In this study we demonstrated inhibition of HIF-1α protein expression and significant inhibition of VEGF production by CaMKII inhibitors. This is an unknown but very interesting effect of the CaMKII inhibitor SMP-114, which is now in clinical trial as DMARD for the treatment of rheumatoid arthritis. This effect may contribute to the anti-arthritic effects of SMP-114.

Acknowledgements
This work has been financially supported by the Dutch Rheumatology Foundation and by Dainippon Sumitomo Pharma, Osaka, Japan. We acknowledge Dr. R. Kuijer of the Department of Biomedical Engineering, UMCG for the use of the hypoxia incubator.

Authors’ contributions
JW and EB conceived and designed the study, IAMvR and BDvdM performed the experiments. MAvL, and MDP participated in interpretation of data. JW, EB, and CGMK have been involved in writing the manuscript. All authors read and approved of the final manuscript.

Competing interests
The authors have received an unrestricted grant from Dainippon Sumitomo Pharma for their research in general. The SMP-114 was provided by Dainippon Sumitomo Pharma free of charge. Dainippon Sumitomo Pharma was not involved in the planning and execution of this study. The authors have no financial interests whatsoever in this company and therefore declare that they have no competing interests.

Received: 26 October 2009 Accepted: 30 March 2010 Published: 30 March 2010
References

1. Mulherin D, Fitzgerald O, Bresnihan B: Synovial tissue macrophage populations and articular damage in rheumatoid arthritis. Arthritis Rheum 1996, 39:115-124.

2. Tak PP, Smets T, Daha MR, Kluun PM, Meijers KA, Brand R, Meinders AE, Breedveld FC: Analysis of the synovial cell infiltrate in early rheumatoid synovial tissue in relation to local disease activity. Arthritis Rheum 1997, 40:217-225.

3. Treeuhaft FS, McCarty DJ: Synovial fluid pH, lactate, oxygen and carbon dioxide partial pressure in various joint diseases. Arthritis Rheum 1971, 14:475-484.

4. Etherington PJ, Winlove P, Taylor P, Paleolog E, Miotla JM: VEGF release is associated with reduced oxygen tensions in experimental inflammatory arthritis. Clin Exp Rheumatol 2002, 20:799-805.

5. Semenza GL, Wang GL: A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Mol Cell Biol 1992, 12:5447-5454.

6. Gaber T, Dziurla R, Tripmacher R, Burmester GR, Buttgereit F: Hypoxia inducible factor (HIF) in rheumatology: low O2! See what HIF can do. Ann Rheum Dis 2005, 64:971-980.

7. Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, Cockman ME, Wykoff CC, Push CW, Maher ER, Ratcliffe PJ: The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 1999, 399:271-275.

8. Schofield CJ, Ratcliffe PJ: Oxygen sensing by HIF hydroxylases. Nat Rev Mol Cell Biol 2005, 6:343-354.

9. Hellwig-Burgel T, Metzen E, Jelkmann W: Review: hypoxia-inducible factor-1 (HIF-1): a novel transcription factor in immune reactions. J Interferon Cytokine Res 2005, 25:297-310.

10. Zhou J, Bruné B: Cytokins and hormones in the regulation of hypoxia inducible factor-1alpha (HIF-1alpha). Cardiovasc Hemostasis Med Chem 2006, 4:189-197.

11. Frede S, Stockmann C, Freitag P, Fandrey J: Bacterial lipopolysaccharide induces HIF-1 activation in human monocytes via p44/p42 MAPK and NF-kappaB. Biochem Biophys Res Commun 2006, 336:517-527.

12. Oda T, Hirota K, Nishi K, Takabuchi S, Oda S, Yamada H, Arai T, Fukuda K, Kita T, Adachi T, Semenza GL, Ohara R: Activation of hypoxia-inducible factor 1 during macrophage differentiation. Am J Physiol Cell Physiol 2009, 291:104-113.

13. Muz B, Khan MN, Kirikidou S, Paleolog EM: The role of hypoxia and HIF-dependent signalling events in rheumatoid arthritis. Arthritis Res Ther 2009, 11:201-209.

14. Brahn E, Banquerigo ML, Lee JK, Park EJ, Fogler WE, Plum SM: An angiogenesis inhibitor, 2-methoxyestradiol, involves rat collagen-induced arthritis and suppresses gene expression of synovial vascular endothelial growth factor and basic fibroblast growth factor. J Rheumatol 2008, 35:2119-2128.

15. Issekutz AC, Sapru K: Modulation of adjuvant arthritis in the rat by 2-methoxyestradiol: an effect independent of an anti-angiogenic action. Int Immunopharmacol 2008, 8:708-716.

16. Rice JW, Veal JM, Fadden RP, Barabasz AF, Partidge JM, Barto TE, Dubois LG, Huang WH, Mabbett SR, Sliwinski MA, Steed PM, Hall SE: Small molecule inhibitors of Hsp90 potently affect inflammatory disease pathways and exhibit activity in models of rheumatoid arthritis. Arthritis Rheum 2008, 58:3765-3775.

17. Yuan G, Nanduri J, Bhatker CR, Semenza GL, Prabhahar NR: Ca2÷ +/calmodulin kinase-dependent activation of hypoxia inducible factor 1 transcriptional activity in cells subjected to intermittent hypoxia. J Biol Chem 2005, 280:4321-4328.

18. Seales EC, Micoli KJ, McDonald JM: Calmodulin is a critical regulator of osteoclastic differentiation, function, and survival. J Cell Biochem 2006, 97:45-55.

19. Liu Y, Yao M, Li N, Wang C, Zheng Y, Cao X: CaMkii promotes TR-beta-triggered proinflammatory cytokine and type 1 interferon production by directly binding and activating TAK1 and IFR3 in macrophages. Blood 2008, 112:4961-4970.

20. Westra J, Dooms-Van Der Meir B, de Boer P, van Leeuwen MA, van Rijswijck MH, Limburg PC: Strong inhibition of TNF-alpha production and inhibition of IL-8 and COX-2 mRNA expression in monocyte-derived macrophages by RWJ 67657, a p38 mitogen-activated protein kinase (MAPK) inhibitor. Arthritis Res Ther 2004, 6:R384-R392.

21. Zhong H, De Marzo AM, Laughner E, Lim M, Hilton DA, Zaggag D, Ruechel P, Isaacs WB, Semenza GL, Simons JW: Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res 1999, 59:5830-5835.

22. Brouwer E, Gouw AS, Posthumus MD, van Leeuwen MA, Boerboom AL, Bijn J, Bos R, Limburg PC, Kalenberg CG, Westra J: Hypoxia inducible factor-1alpha (HIF-1alpha) is related to both angiogenesis and inflammation in rheumatoid arthritis. Clin Exp Rheumatol 2009, 27:945-951.

23. Gastromanolaki A, Sivridis E, Maltezos E, Athanassou N, Papazoglou O, Gatter KC, Harris AL, Koukorikis M: Upregulated hypoxia inducible factor-1alpha and -2alpha pathway in rheumatoid arthritis and osteoarthritis. Arthritis Res Ther 2003, 5:R193-R201.

24. Peters CL, Morris CJ, Mapp PI, Blake DR, Lewis CE, Winrow VR: The transcription factors hypoxia-inducible factor 1alpha and Ets-1 colocalize in the hypoxic synovium of inflamed joints in adjuvant-induced arthritis. Arthritis Rheum 2004, 50:291-296.

25. Hollander AP, Corke KP, Freemont AJ, Lewis CE: Expression of hypoxia-inducible factor 1alpha by macrophages in the rheumatoid synovium: implications for targeting of therapeutic genes to the inflamed joint. Arthritis Rheum 2001, 44:1540-1544.

26. Kimura K, Iwano M, Higgs DF, Yamauchi Y, Nakatani K, Harada K, Kubo A, Aki Y, Rankin EB, Nilsson EG, Haase VH, Saito Y: Stable expression of HIF-1alpha (in tubular epithelial cells promotes interstitial fibrosis. Am J Physiol Renal Physiol 2008, 295:F1023-F1029.

27. Shin DH, Kim JT, Jung YJ, Kim KE, Jeong JM, Chun YS, Park JW: Preclinical evaluation of YC-1, a HIF inhibitor, for the prevention of tumor spreading. Cancer Lett 2007, 235:107-116.

28. Chung JC, Yang JS, Huang LJ, Lee FY, Tsai SC, Lin KL, Wang SF, Kuo SC: Protective approach to studying the cytotoxicity of YC-1 on U937 leukemia cells and antileukemia activity in orthotopic model of leukemia mice. Proteomics 2007, 7:3305-3317.

29. Lee YS, Lan Tran HT, Van Ta TQ: Regulation of expression of matrix metalloproteinase-9 by JNK in RAW 264.7 cells: presence of inhibitory factor(s) suppressing MMP-9 induction in serum and conditioned media. Exp Mol Med 2009, 41:259-268.

30. Liu FQ, Liu Y, Liu VC, Lamb JR, Tam PK, Chen Y: Hypoxia modulates lipopolysaccharide induced TNF-alpha expression in murine macrophages. Exp Cell Res 2008, 314:1327-1336.

31. Fang HY, Hughes R, Murdoch C, Coffelt SB, Biswas SK, Harris AL, Johnson RS, Intzyryaz HZ, Simon MC, Fredlund E, Green FR, Rius J, Lewis CE: Hypoxia-inducible factors 1 and 2 are important transcriptional effectors in primary macrophages experiencing hypoxia. Blood 2009, 114:844-859.

32. Haas CS, Arin MA, Ruth JH, Allen BL, Ahmed S, Pakozdi A, Woods JM, Shahrara S, Koch AE: In vivo inhibition of angiogenesis by interferon-13 gene therapy in a rat model of rheumatoid arthritis. Arthritis Rheum 2007, 56:2533-2548.

33. Strunk J, Bundke E, Lange U: Anti-TNF-alpha antibody Infliximab and glucocorticoids reduce serum vascular endothelial growth factor levels in patients with rheumatoid arthritis: a pilot study. Rheumatol Int 2006, 26:252-256.

Pre-publication history

The pre-publication history for this paper can be accessed here: http://www.biomedcentral.com/1471-2474/11/61/prepub

doi:10.1186/1471-2474-11-61

Cite this article as: Westra et al.: Expression and regulation of HIF-1alpha in macrophages under inflammatory conditions; significant reduction of VEGF by CaMkii inhibitor. BMC Musculoskeletal Disorders 2010 11:61.